A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.

Exclusion Criteria

• •Forms of psoriasis other than moderate to severe plaque-type psoriasis, e.g. drug-induced psoriasis at Screening.
• •Patients with previous treatment with any agent targeting interleukin (IL)-17 directly or IL-17 receptor A (e.g. secukinumab, ixekizumab, or brodalumab).
• •Pregnant or nursing (lactating) women
• •Women of child-bearing potential unless they use effective contraception